Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

Biotech Investing

Iovance Biotherapeutics (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $11.50 per share. As quoted in the company press release: Iovance intends to use the proceeds from this …

Iovance Biotherapeutics (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $11.50 per share.
As quoted in the company press release:

Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund its planned clinical trials for its current product candidates, including a planned Phase 2 clinical trial of LN-145 for the treatment of non-small cell lung cancer (NSCLC), in collaboration with MedImmune, as well as the NSCLC study in collaboration with the H.

Click here to read the full press release.

The Conversation (0)
×